Certara, Inc. CERT 深 滬
等待開盤 08-20 09:30:00 美东时间
10.98
-0.200
-1.79%
華盛通- 最 高11.27
- 今 開11.24
- 成交量 53.38万股
- 最 低 10.90
- 昨 收 11.18
- 總市值 17.79亿
- 52周最高 15.69
- 市盈率 靜 --
- 換手率 0.33%
- 52周最低 8.635
- 委 比 2.12%
- 總股本 1.62亿
- 歷史最高 45.48
- 量 比 0.55
- 振 幅 3.31%
- 歷史最低 8.635
- 每 手 1
- 風險率 1.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | DoorDash获上调目标价从230美元升至300美元； 摩根大通上调Shopify目标价从115美元升至179美元
今日重点评级关注：HC Wainwright & Co.：维持FibroGen"买入"评级，目标价从10美元升至43美元；摩根大通：维持Cogent Biosciences"超配"评级，目标价从29美元升至30美元
08-08 09:34
UBS Maintains Buy on Certara, Lowers Price Target to $15
UBS analyst Dan Leonard maintains Certara (NASDAQ:CERT) with a Buy and lowers the price target from $17.5 to $15.
08-08 01:20
Certara Q2 Adj. EPS $0.07 Misses $0.10 Estimate, Sales $104.600M Beat $104.140M Estimate
Certara (NASDAQ:CERT) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.10 by 30 percent. This is unchanged from the same period last year. The company reported quarterly
08-07 04:19
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling
Certara's Simcyp Simulator has been formally qualified by the European Medicines Agency (EMA) for regulatory submissions across the EU, making it the first PBPK modeling platform to receive this designation. This qualification simplifies the drug submission process by eliminating the need to re-establish the platform's credibility for specific contexts of use. Simcyp can now replace clinical DDI studies in various scenarios, covering 6 CYP enzyme...
08-04 06:00
美方利用微软Exchange漏洞攻击我军工企业！详情披露
据中国网络空间安全协会微信公众号消息，国家互联网应急中心(CNCERT)监测发现，近年来，美国情报机构将网络攻击窃密的重点目标瞄准我高科技军工类的高校、科研院所...
08-01 10:36
Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform
Certara, Inc. appoints Christopher Bouton, Ph.D., as Chief Technology Officer to lead the development of a next-generation AI and biosimulation-enabled drug development platform. Bouton, formerly founder and CEO of Vyasa Analytics (acquired by Certara in 2022), brings expertise in AI, drug discovery, and development. His leadership has advanced Certara's AI-driven biosimulation and virtual trials, enhancing efficiency and success rates in bringin...
07-31 20:15
A Look at Waystar Holding's Upcoming Earnings Report
Waystar Holding (NASDAQ:WAY) will release its quarterly earnings report on Wedn...
07-30 03:01
星巴克在欧洲推出可回收且可家庭堆肥的环保外带杯 原材料采用芬林纸板产品
（来源：中纸网） 星巴克与合作伙伴共同研发了一款全新的环保外带杯，芬林纸板参与了此次重新设计项目。这款外带杯不仅易于回收，还可在家庭环境中进行堆肥处理...
07-19 11:06
dynaCERT’s HydraGEN™ Technology Pioneers Emission Reduction at French Port
dynaCERT ( ($TSE:DYA) ) has issued an update. dynaCERT has announced the deploy...
07-17 17:33
